AI-Guided Lead Discovery for Small-Molecule Drug Discovery
Synfini turns hits into validated lead molecules by designing, making, testing, and analyzing compounds in one place, so each round learns from the last.
Tell us about your target and where your hits stand.
What Is Lead Identification in Drug Discovery?
Lead identification is the stage of the drug discovery process where researchers turn hits into lead molecules: compounds with confirmed activity against a target protein and early structure activity relationships.
It decides which series reach the later stages of drug development.
Where Lead Discovery Loses Time
High throughput screening (HTS) tests many compounds quickly, but most hits fall away on confirmation. AI design has the opposite problem: it proposes thousands of potential leads that often cannot be made.
Either way, progress slows when design, synthesis, and testing sit with different teams and information waits on each handoff.
How Synfini Finds Lead Molecules
AI design, route planning, and automated synthesis work in combination, so every compound we score is one we can make.
Models built for your target
Score potential leads for potency, selectivity, and ADMET. Scaffold hopping opens new chemical space.
Routes before designs
Every design gets a practical route. Parallel library synthesis explores each core.
Hits confirmed
Compounds run in your assays, and results return as structured data.
SAR every round
Structure activity relationships retrain the models before the next design round.
What You Bring and What We Run
We are happy to start from HTS hits, fragments, published articles, or only a validated target.
You bring
- A validated target protein
- Any existing hits and data
- Your assays and lead criteria
Synfini runs
- Target models and analog design
- Route planning and automated synthesis
- SAR analysis and model retraining
Step 1A conversation about your target and hits
Step 2A plan built around your lead criteria
Step 3DMTA cycles until a series is ready for lead optimization
A Worked Example with Transcripta Bio
In a collaboration announced on October 7, 2026, Transcripta Bio and Synfini identified a lead candidate against a key driver of Huntington’s disease progression in a matter of weeks.
Transcripta brought the target rationale and ran the confirmatory assays. Synfini built the predictive models, ran multiparameter optimization, and synthesized the compounds.
This is a lead-stage result. Lead-stage potency does not predict downstream success.
AI-Guided Lead Discovery vs. High Throughput Screening
The two methods often work together. The difference is how the next compounds are chosen.
| High throughput screening | Synfini | |
|---|---|---|
| Starting point | A large compound library | Your target, plus any hits |
| Next round guided by | Hit lists and follow-up screens | SAR data retraining the models |
| What you get | Hits that need confirmation | Leads with SAR and a synthesis route |
Who This Is For
Biotech teams and research institutes that need medicinal chemistry without building chemistry resources in-house.
Hits, no chemistry team
You need a partner to design and make compounds around your hits.
A target, no hits yet
You want promising candidates without a large screening campaign.
A lead decision ahead
You need supporting SAR data to choose which series moves forward.
Frequently Asked Questions
What is lead discovery in drug discovery?
Lead discovery is finding lead molecules: compounds with confirmed activity against a target and properties worth optimizing. It covers hit identification, hit to lead, and lead identification.
What is the difference between hit identification and lead identification?
Hit identification finds compounds with any activity of interest, usually through screening. Lead identification determines which hits, after modifications, show the potency and specificity required to progress.
What happens during hit to lead?
Hits are confirmed, analogs are made, and structure activity relationships are evaluated. The aim is a few validated leads.
How does high throughput screening (HTS) fit into lead discovery?
HTS screens libraries of compounds against target proteins to find starting hits. Synfini can begin from HTS hits, or design starting points when no screening data exists.
What makes small molecules good leads?
Reproducible potency, a clear SAR trend, acceptable early toxicity signals, and a synthesis route that can ensure a steady supply of analogs.
When does a program move to lead optimization?
When a series meets the agreed lead criteria, it moves to closed-loop lead optimization toward drug candidates.
Find Leads for Your Target
Learn how Synfini can move your program from hits to a validated lead series. A member of our team will reply within 1 business day.
Prefer email? info@synfini.com
